Obstacles and Opportunities to Improve Antiretroviral Regimen Access in Low-Income Countries
University of Pennsylvania - Department of Medicine, Division of Infectious Diseases
Brook K. Baker
Northeastern University - School of Law
August 1, 2010
Current HIV/AIDS Reports, Vol. 7, No. 3, pp. 161-167, August 2010
Northeastern University School of Law Research Paper No. 72-2012
Increasing evidence suggests that dramatically increasing access to effective and well-tolerated antiretroviral medications is key to reversing the HIV pandemic. Currently used first-line therapies in developing countries have multiple toxicities that cause significant morbidity and mortality. New World Health Organization HIV treatment guidelines support earlier treatment initiation and the use of less toxic first-line therapies. Adoption of these guidelines requires political and financial commitment from multiple stakeholders including country governments and donors. This review summarizes the major adverse effects associated with commonly used ARV regimens in low-income countries and also analyzes some of the barriers and potential solutions that affect the ability of low-income countries to implement the new World Health Organization guidelines.
Keywords: Antiretroviral medication, low-income countries, medication pricing, universal access
Date posted: January 5, 2012
© 2016 Social Science Electronic Publishing, Inc. All Rights Reserved.
This page was processed by apollobot1 in 0.156 seconds